Amazon Q Developer is a useful AI-powered coding assistant with chat, CLI, Model Context Protocol and agent support, and AWS ...

Recursion Pharmaceuticals' work could change the way that drugs are developed. Its pipeline features some exciting candidates, and it's partnering with major drugmakers. However, Recursion still needs ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...

The Florida government is ridding the Everglades of invasive pythons by allowing fashion brans to turn them into luxury accessories. Inverse Leathers Shopping will now save the planet. Florida ...

FORTUNATELY, NOBODY WAS INJURED. CONTROLLING THE PYTHON POPULATION HERE IN FLORIDA, GOVERNOR DESANTIS SPOKE IN STUART TODAY ABOUT SOME NEW ACTIONS THE STATE PLANS TO TAKE TO CONTROL THE GROWTH OF ...

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) stock is surging on Wednesday, without any news to justify the movement. Session volume stands at 69.3 million versus the average volume of 26.9 million, ...

This week, I had to make one of the most difficult decisions of my career: saying goodbye to 20% of the team at Recursion. The process was extraordinarily painful, and the costs were heartbreakingly ...

I now rate Recursion Pharma a sell due to disappointing recent trial updates and uncertain future prospects. REC-4881's phase 2 TUPELO trial showed mixed results, with one patient experiencing a ...

OCHOPEE, Florida (Reuters) -Amy Siewe was a successful real estate agent -- but her life changed after she captured her first python in Florida's Everglades. "I just had this fascination with snakes.

June 10 (Reuters) - Recursion Pharmaceuticals (RXRX.O), opens new tab said on Tuesday it would lay off about 20% of its workforce as the biotech company tries to cope with an industry-wide funding ...